These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26152395)

  • 1. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.
    Kroksveen AC; Jaffe JD; Aasebø E; Barsnes H; Bjørlykke Y; Franciotta D; Keshishian H; Myhr KM; Opsahl JA; van Pesch V; Teunissen CE; Torkildsen Ø; Ulvik RJ; Vethe H; Carr SA; Berven FS
    Proteomics; 2015 Oct; 15(19):3361-9. PubMed ID: 26152395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.
    Kroksveen AC; Aasebø E; Vethe H; Van Pesch V; Franciotta D; Teunissen CE; Ulvik RJ; Vedeler C; Myhr KM; Barsnes H; Berven FS
    J Proteomics; 2013 Jan; 78():312-25. PubMed ID: 23059536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis.
    Mattsson N; Rüetschi U; Podust VN; Stridsberg M; Li S; Andersen O; Haghighi S; Blennow K; Zetterberg H
    J Neurochem; 2007 Dec; 103(5):1932-9. PubMed ID: 17953655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the biochemistry and identifying biomarkers to multiple sclerosis.
    Martins-de-Souza D; Farias AS
    Proteomics; 2015 Oct; 15(19):3281-2. PubMed ID: 26314682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid.
    Timirci-Kahraman O; Karaaslan Z; Tuzun E; Kurtuncu M; Baykal AT; Gunduz T; Tuzuner MB; Akgun E; Gurel B; Eraksoy M; Kucukali CI
    Acta Neurol Belg; 2019 Mar; 119(1):101-111. PubMed ID: 29873030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.
    Comabella M; Fernández M; Martin R; Rivera-Vallvé S; Borrás E; Chiva C; Julià E; Rovira A; Cantó E; Alvarez-Cermeño JC; Villar LM; Tintoré M; Montalban X
    Brain; 2010 Apr; 133(Pt 4):1082-93. PubMed ID: 20237129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.
    Kroksveen AC; Guldbrandsen A; Vedeler C; Myhr KM; Opsahl JA; Berven FS
    Acta Neurol Scand Suppl; 2012; (195):90-6. PubMed ID: 23278663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid proteomics in multiple sclerosis.
    Kroksveen AC; Opsahl JA; Guldbrandsen A; Myhr KM; Oveland E; Torkildsen Ø; Berven FS
    Biochim Biophys Acta; 2015 Jul; 1854(7):746-56. PubMed ID: 25526888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.
    Checa A; Khademi M; Sar DG; Haeggström JZ; Lundberg JO; Piehl F; Olsson T; Wheelock CE
    Mult Scler; 2015 Sep; 21(10):1271-9. PubMed ID: 25480867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
    Salvisberg C; Tajouri N; Hainard A; Burkhard PR; Lalive PH; Turck N
    Proteomics Clin Appl; 2014 Apr; 8(3-4):185-94. PubMed ID: 24488530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.
    Shi Y; Ding Y; Li G; Wang L; Osman RA; Sun J; Qian L; Zheng G; Zhang G
    Front Immunol; 2021; 12():700031. PubMed ID: 34489947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study.
    Valko PO; Roschitzki B; Faigle W; Grossmann J; Panse C; Biro P; Dambach M; Spahn DR; Weller M; Martin R; Baumann CR
    J Sleep Res; 2019 Jun; 28(3):e12721. PubMed ID: 29961995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.